Skip to main content

Table 3 Impact of LDL cholesterol, triglycerides, HDL cholesterol, and adiponectin on the level of MDA-LDL in the multivariate analyses

From: Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease

 

Model 1

Model 2

 

β

p

β

p

LDL cholesterol

0.452

<0.0001

0.444

<0.0001

Triglycerides*

0.317

<0.0001

0.318

<0.0001

HDL cholesterol

−0.137

0.049

−0.139

0.048

Adiponectin*

−0.049

0.481

−0.032

0.648

  1. Abbreviations: HDL high-density lipoprotein, LDL low-density lipoprotein, MDA-LDL malondialdehyde-modified LDL.
  2. In model 1 (R2 = 0.361), LDL cholesterol, triglycerides, HDL cholesterol, and adiponectin were included as the variables in the multiple regression analysis. In model 2 (R2 = 0.365), medications (metformin and α-glucosidase inhibitors) were added to the variables for the model 1 analysis.
  3. *Log-transformed values were subjected to statistical analyses.